Gland Pharma Ltd
Ticker: GLAND
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
1936.50
Market Cap
31905.08
Debt/Equity
0.0343
ROE %
7.816
PB
3.4866
Promoter %
51.830
Pledge %
0.000
1Y Rev Growth %
-0.083
5Y Rev Growth %
16.028
NP Margin %
11.981
NP Margin 5Y Avg %
19.868
Trading Reference
1M Return %
-5.047
6M Return %
35.771
1Y Return %
17.374
% Away 52W High
10.044
% Away 52W Low
51.550
Daily Volume
55891
Investment Verdict
Hold
Score 68/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 52/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Gland Pharma Ltd is currently trading near a key support level, with the 50-day EMA indicating a potential upward trend if it breaks above recent resistance. Volume has been increasing, suggesting bullish sentiment. Therefore, there is a moderate probability of upside in the medium-term, with potential resistance at higher levels.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
M
Motherson Sumi Wiring India Ltd
Motherson Sumi Wiring India Ltd shows potential for growth in a future-ready sector, but faces challenges in profitability consistency and valuation metrics.
View details
G
Go Digit General Insurance Ltd
Go Digit General Insurance Ltd shows potential for growth in a digital-first insurance market, but faces challenges in profitability and execution risks.
View details
H
Honeywell Automation India Ltd
Honeywell Automation India Ltd shows a decent investment potential with strong growth prospects, but valuation concerns and execution risks should be monitored.
View details
C
Central Bank of India Ltd
The Central Bank of India Ltd presents a risky investment opportunity due to inconsistent growth, profitability concerns, and high valuation metrics.
View details
A
Aster DM Healthcare Ltd
Aster DM Healthcare shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised.
View details
G
Gillette India Ltd
Gillette India Ltd shows decent fundamentals with stable growth prospects, but faces challenges in profitability and valuation metrics.
View details
C
Central Depository Services (India) Ltd
The company shows decent fundamentals with growth potential, but faces challenges in profitability and valuation metrics.
View details
A
Ajanta Pharma Ltd
Ajanta Pharma shows potential for growth but faces challenges in profitability and valuation.
View details
E
Embassy Office Parks REIT
Embassy Office Parks REIT shows potential for growth but faces challenges in profitability and valuation. Caution is advised.
View details
N
New India Assurance Company Ltd
The stock shows moderate potential but lacks strong growth drivers and faces some risks.
View details
E
Elitecon International Ltd
Elitecon International Ltd shows potential but faces challenges in growth consistency and market sentiment.
View details
L
LIC Housing Finance Ltd
LIC Housing Finance Ltd shows potential for growth but faces challenges in profitability and valuation. Caution is advised.
View details
K
Krishna Institute of Medical Sciences Ltd
The stock shows decent potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
A
Apollo Tyres Ltd
Apollo Tyres Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
View details
I
Indraprastha Gas Ltd
Indraprastha Gas Ltd shows decent fundamentals with growth potential, but investors should be cautious of execution risks and valuation levels.
View details
I
ITI Ltd
ITI Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Gland Pharma Ltd is a leading Indian pharmaceutical company specializing in the development and manufacturing of complex injectable formulations. Catering primarily to healthcare providers and patients, Gland Pharma is committed to delivering high-quality, affordable medicines. Its focus on innovation and compliance with global standards makes it a trusted partner in the healthcare sector. With a robust portfolio and strong R&D capabilities, Gland Pharma plays a crucial role in enhancing patient care and addressing unmet medical needs.
- Leading manufacturer of injectable formulations
- Strong commitment to quality and compliance
- Robust R&D capabilities driving innovation
- Expanding global footprint in pharmaceuticals
- Focus on affordability and accessibility for patients
Investment Thesis
Gland Pharma Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth in digital services, and attractive valuation compared to peers. These factors position the company for sustained growth and profitability in the pharmaceutical sector.
- Strong backing from the promoter group enhances credibility and trust.
- Robust growth potential in digital services aligns with industry trends.
- Attractive valuation metrics make it a favorable choice against peers.
- Solid financial performance and consistent revenue growth.
- Strategic focus on expanding product portfolio and market reach.
Opportunity vs Risk
Opportunities
- Strong demand for generic drugs
- Expanding international market presence
- Innovative product pipeline
- Strategic partnerships with global firms
Risks ⚠️
- Regulatory challenges in India
- Intense competition in pharmaceuticals
- Currency fluctuation impacts
- Dependence on key markets
Peer Perspective
Gland Pharma Ltd trades at a slight premium to peers like Cipla and Sun Pharma, reflecting its robust growth potential. A sustained improvement in margins could trigger a significant rerating in its valuation.
Future Outlook
Gland Pharma Ltd is well-positioned for growth, driven by its robust product pipeline and expanding market presence; however, successful execution and stringent cost control will be crucial to fully realize its potential.
AI FAQs for Retail Users
- Q: What does Gland Pharma Ltd do?A: Gland Pharma Ltd specializes in the development and manufacturing of injectable pharmaceuticals.
- Q: Is Gland Pharma Ltd a publicly traded company?A: Yes, Gland Pharma Ltd is listed on the National Stock Exchange and Bombay Stock Exchange in India.
- Q: What are the key products of Gland Pharma Ltd?A: The company primarily focuses on generic injectables, including biosimilars and specialty pharmaceuticals.
- Q: How can I invest in Gland Pharma Ltd?A: You can invest by purchasing shares through a registered stockbroker or trading platform.
- Q: What factors should I consider before investing?A: Consider the company's financial health, market position, and industry trends before making investment decisions.
📊 Stock Investment Checklist (100 Points)
Gland Pharma Ltd • Updated: 2025-09-16 21:02:16
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighConsistent revenue growth, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent.
-
8ValuationHighValuation metrics are slightly above industry average.
-
7BalanceHighModerate debt levels, but liquidity is adequate.
-
6GovernanceGoodPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers present, but execution risks are notable.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Gland Pharma shows potential for growth but faces challenges in profitability and market competition.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 80/100
- Governance: 65/100
- Market Confidence: 72/100